To: 5.1.2e , 5.1.2e . (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e , 5.1.2e . 5.1.2e (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e [5.1.2e .2 5.1.2e 5.1.2e (5.1.2e)[5.1.2e @minvws.nl]
From: 5.1.2e 5.1.2e e 5.1.2e)
Sent: Thur 3/25/2021 7:24:50 AM
Subject: FW: AstraZeneca: AZD1222 US Phase III primary analysis confirmssafety and efficacy
Received: Thur 3/25/2021 7:24:51 AM

Ter info.

Groet,

5.1.2e

Verzonden met BlackBerry Work
(www.blackberry.com)

Van: 5.1.2e , 5.1.2e < 5.1.2e @astrazeneca.com>
Datum: donderdag 25 mrt. 2021 8:11 AM
Aan: Minister van VWS < 5.1.2e @minvws.nl>
Kopie: 5.1.2e 5.1.2e e 5.1.2e) < 5.1.2e @minvws.nl>, 5.1.2e , 5.1.2e . < 5.1.2e @minvws.nl>, 5.1.2e , 1.2. (5.1.2e)
< 5.1.2e @minvws.nl>, 5.1.2e 5.1.2e < 5.1.2e @gmail.com>, 5.1.2e , 5.1.2e < 5.1.2e @astrazeneca.com>
Onderwerp: AstraZeneca: AZD1222 US Phase III primary analysis confirms safety and efficacy

Dear Minister De Jonge
Dear Minister Van Ark,

I wanted to keep you informed that the high-level positive results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy is consistent with the pre-specified interim analysis announced on Monday 22 March.

- The primary endpoint, **vaccine efficacy at preventing symptomatic COVID-19, was 76%** occurring 15 days or more after receiving two doses given four weeks apart.
- A key secondary endpoint, **preventing severe or critical disease and hospitalisation, demonstrated 100% efficacy.**
- Results were **comparable across age groups**, with **vaccine efficacy of 85%in adults 65 years and older.**
- The vaccine was **well tolerated and no safety concerns related to the vaccine were identified.**

This primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis.

These results have been presented to the independent Data Safety Monitoring Board (DSMB). The primary analysis is pre-specified in the protocol and will be the basis for the Emergency Use Authorization submission to the Food and Drug Administration. AstraZeneca will submit the primary analysis for peer-review publication in the coming weeks.

Please find the official company statement below and do not hesitate to reach out should you have any questions.

Sincerely,

5.' 5.1.2e

5.1.2e 5.1.2e
AstraZeneca
M: +31 5.1.2e
5.1.2e @astrazeneca.com
5.1.2e
5.1.2e @astrazeneca.com

Click here to view online



AZD1222 US Phase III primary analysis confirms safety and efficacy

25 March 2021

Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021.

Read more

RSS Feed Follow us on Twitter Follow us on LinkedIn

Legal notice and Terms of Use | Privacy policy | Cookie policy | Site map | © AstraZeneca 2021

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com